INTRODUCTION AND OBJECTIVES: Assess the feasibility and the accuracy of targeted prostate biopsy with standard (systematic 12-core) biopsies after fusion imaging of choline-PET/CT (choline-PET) and multiparametric MRI (mpMRI) with 3D-transrectal ultrasound (TRUS) to detect prostate cancer. The Fusion of the two modality with echography 3d was try to compare the diagnostic performance for localization of primary PCa with (mpMRI) and last generation of PET/CT (Biograph mCT Flow, Siemens).
METHODS: Within a prospective single-center study, from December 2014 to October 2016, 31 patients with a rising PSA ? 10ng/ ml or with an history of a negative prostate biopsies were included, and performed a choline-PET and a mpMRI. PET and T2-weighted MR volumes of the prostate were spatially registered using commercially available software. Biopsy targets were selected on both modalities. TRUS biopsy using the real-time 3D TRUS-tracking system (Urostation Touchâ, Koelis, France), which enabled US-guided and/or MR/US fusion targeted biopsies. The biopsy procedure was performed after registration of real-time TRUS with mpMRI and choline-PET by the same operator, using 3D TRUS-tracking system. At the time of biopsy, volume data of the mpMRI and PET 18-ch was elastically fused with TRUS. Each target was biopsied twice. Histologic results were determined from standard and targeted biopsy cores.
RESULTS: Mean PSA was 13.01 ng/ml (5.32-73) . Mean number of biopsy was 16 (13-21) and mean prostate volume was 63.41 cc . The cancer detection rate was 69%. The cancer detection rate with standard biopsies off target was 42% and with prostate targeted biopsy was 50% using PET, 65% using mpMRI with a sensibility of 72%, 94%, 100% respectively for PET, mpMRI or both . The average number of positive cores was respectively 1.77 (1-7) ,2.74 (3-11) for PET and mpMRI.
CONCLUSIONS: We demonstrated the feasibility and accuracy of multimodal image registration for targeted prostate biopsies with echography 3D to define localization of prostate cancer, compared to standard biopsies. It was very interesting to observe sometimes a great difference in the distribution of PET choline targets and mpMRI targets in the prostate. mpMRI was probably better than PET to detected prostate cancer but it could be complementary. A new study with a novel ligands targeting prostate specific membrane antigen (PSMA) could improve our clinical results.
Source of Funding: none

MP77-03 TARGETED 11C-CHOLINE PET/CT/TRUS SOFTWARE FUSION-GUIDED PROSTATE BIOPSY HAS IN MEN WITH PERSISTENTLY ELEVATED PSA AFTER PREVIOUS NEGATIVE BIOPSY
INTRODUCTION AND OBJECTIVES: Multiparametric MRI (mpMRI) has become the preferred method for detecting prostate cancer (PCa) foci after a negative biopsy and has been incorporated into EAU guidelines. Although the NPV of mpMRI is around 90-95%, some, potentially important, cancers may be mpMRI-invisible. Some men may have contraindications to MRI (i.e. claustrophobic patients or presence of metallic implants). 11C-choline PET is a promising tool for the investigation of PCa but studies have provided equivocal results because of overlap with benign prostate hyperplasia (BPH) and prostatitis. The aim of this study was to assess the potential clinical impact of 11C-choline PET/TRUS fusion-guided prostate biopsy in men with persistently elevated PSA after negative biopsy and negative or contraindicated mpMRI.
METHODS: Clinical data were acquired as part of a prospective ongoing observational study: MpMRI_ICH_1398; Ethical Committee approval March 2015. Patients with persistently elevated PSA, with or without ASAP and/or HG-PIN and negative DRE, after at least one negative biopsy (at least 12 cores for each biopsy course) and a negative (PI-RADSv.2 <3) or contraindications for mpMRI were the nested cases. The 11C-choline was synthesized using a General Electric TracerLab FXc module and administered in a total activity of 250-400 MBq. Total-body images were obtained with a PET/CT Discovery 690 (GE Healthcare) and acquired using an automated dose modulation (maximal 140 mA, 140 kVp), 64x3.75 mm collimation, 3.75 mm slice thickness, 0.5s rotation time, pitch 0.984:1. Reconstructed images of the pelvis were obtained and displayed for reading on an OsiriX MD Imaging workstation. The Bio-Jet fusion system and software (D&K Technologies, Barum, Germany) were used. Biopsies, transrectal or transperineal according to lesion site, were performed with patients in the dorsal lithotomic position, under antibiotic prophylaxis and local anaesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz). The primary endpoint was to assess whether 11C-choline PET/ CT was able to determine the presence and the topographical distribution of the tumour foci. Data were complemented by statistical analysis.
RESULTS: Of 298 consecutive patients enrolled from April 2015 to September 2016, 14 (mean age 65.3AE8.3 years; tPSA 12.7AE3.9 ng/ml) were cases of interest and underwent. PET documented 26 suspect lesions. The uptake values of ROIs on were: mean SUVmax 5.43 (AE1.45; range: 1.9-8.3), mean SUVbackground 3.34 (AE0.57; range1.6-5.5), SUVratio to background 1.64 (AE0,35; range 1.16-2.51). PET/TRUS fusion biopsy was feasible in all patients. PCa was detected in 6 patients (42.8%). Of 77 cores, 23 (29.8%) were positive. Four patients harboured a significant PCa (GS > 6). The mean extension (length in mm) of PCa was higher in GS>6 patients than GS¼6 patients (10,4 mm versus 5.5). We found no significant difference in mean values for SUVmax and SUVratio between benign (BPH + prostatitis) and malignant lesions. Patients with benign lesions presented a mean SUVmax and SUVratio of 5.77 and 1.64; patients with PCa had a mean SUVmax and SUVratio of 4.81 and 1.38 (p> 0.05).
CONCLUSIONS: Our findings showed a relative low accuracy of 11C-choline PET for detection of PCa, although patients with an aggressive PCa (GS>6) had a higher, but not statistically significant, uptake. Further studies using more specific radiotracers (i.e. 68Ga-PSMA PET/CT Imaging) are mandatory before introduction of this technique into clinical practice. failure following salvage therapy after prostatectomy is poorly understood. The objective of this study is to identify sites of cancer recurrence in patients who received hormonal therapy (HT), radiation therapy (RT) or combination of HT and RT following prostatectomy and subsequently developed PSA progression. METHODS: Between January 2008 and June 2016, 2466 patients underwent imaging for PSA recurrence. From this cohort 216 received RT, HT or RT+HT postoperatively and underwent 11C-choline PET scan and mpMRI. Additionally, clinical factors (ie. PSA at imaging) associated with recurrence were also evaluated. Local recurrence was defined as positive imaging within prostate bed. Metastatic recurrence included recurrent disease of pelvic/distant nodes as well as osseous disease.
Source of Funding: None
RESULTS: Among 216 patients with PSA progression, 26 (12.0%) patients exhibited local recurrence, 34 (15.8%) had local and distant metastatic disease, and 156 (72.2%) had metastatic disease. Table 1 describes patterns of recurrence. Mean PSA was 4.47, 6.87, and 10.63 in patients with local recurrence, local and metastatic recurrence, and metastatic recurrence, respectively (p¼0.21). When recurrence patterns were compared with postoperative treatment-naïve patients (Sobol et al JU 2016) , patients receiving postoperative therapy had higher rates of metastatic recurrence (72% vs. 44%) while treatment-naïve patients had higher rates of local recurrence (34% vs 12%; both p<0.0001).
CONCLUSIONS: Utilization of mpMRI and 11C-choline PET imaging in the evaluation of PSA progression after postoperative therapy reveals varied recurrence patterns, with the majority of patients having evidence of metastatic disease, when compared with a treatment-naïve cohort. Approximately 12% of patients who failed postoperative therapy after prostatectomy may be eligible for additional local therapy. Prudent utilization of advanced imaging techniques may optimize and guide therapeutic options among patients who develop PSA progression following postoperative therapy potentially avoiding unnecessary or ineffective treatments.
MP77-05 SIMPLE PROSTATE BIOPSY PROTOCOL WITH AUGMENTED ANTIBIOTICS DECREASES COMPLICATIONS AND ADMISSIONS IN VETERANS
Kimberly A Maciolek*, Sara L Best, Wade A Bushman, David F Jarrard, Tracy M Downs, E Jason Abel, Kyle A Richards, Madison, WI INTRODUCTION AND OBJECTIVES: Complications following prostate biopsy are rare but can be devastating. The American Urologic Association (AUA) Quality Improvement Summit in 2014 recommended identifying high risk patients and considering augmented antibiotics. We prospectively implemented a biopsy protocol to identify high-risk patients for bleeding or infections and use augmented antibiotics with the objective of reducing complications.
METHODS: Overall, 637 consecutive patients from June 1, 2014 to August 30, 2016, who underwent prostate biopsy at our Veterans Affairs hospital were evaluated. The prostate biopsy protocol required the provider to document infectious risk factors including prior UTI, antibiotic exposure, and/or recent biopsy to alert the prescriber to substitute IM ceftriaxone for oral ciprofloxacin in high-risk patients. Patients were also monitored closer for bleeding after the biopsy, especially those driving !2 hours. We defined complications as any deviations from normal post-biopsy activities. Comparisons were made between pre/post protocol cohorts, and logistic regression was used to identify risk factors for admissions or complications.
RESULTS: The median age was 67 (IQR 64-69, p¼0.4) in both groups (pre n¼334, post n¼303). 45 patients were deemed high infectious risk with the following patient-reported events: 22 patients with antibiotics for recent UTI, 10 patients with history of complicated UTI/ prostatitis, 16 patients with prostate biopsies within 6 months and 3 patients with clean intermittent catheterization or indwelling catheter. Pre-protocol, 98.8% patients received ciprofloxacin empirically; postprotocol, 85.7% received ciprofloxacin and 14.3% received ceftriaxone (p<0.001). There were no deaths in either group. The 30-day complication rates pre-and post-protocol were 16.2% and 8.5% (p¼0.001) with infectious complication rates of 1.2% and 1.7% (p¼0.74). There was a decrease in 30-day hospitalization rate in the post-protocol group vs. the pre-protocol group (1% vs. 3.6%, p¼0.04). On logistic regression, there were reduced odds of 30-day complications (OR 0.48, p¼0.004) and 30-day hospitalization (OR 0.27, p¼0.04) in the postprotocol group.
CONCLUSIONS: A screening protocol for bleeding and infectious risks prior to prostate biopsy provides a more targeted approach for selecting prophylactic antibiotics and closer monitoring post-biopsy for bleeding. Rates of infection overall were quite low. Our results suggest that the protocol has a favorable impact on complication and hospitalization rates.
